Howard Rutman is the founder of Xalud Therapeutics. Xalud Therapeutics has raised $30M in total funding. Latest round: Series C.
Howard Rutman, MD serves as the Chief Development Officer of Xalud Therapeutics. In this role, he has contributed to company-related clinical reporting and discussions regarding the progress of Xalud's XT-150 program for osteoarthritis and neuropathic pain.
Full founder directory · Investor directory · Company funding database · Fundraising library